scholarly journals Impact of interfractional target motion in locally advanced cervical cancer patients treated with spot scanning proton therapy using an internal target volume strategy

2021 ◽  
Vol 17 ◽  
pp. 84-90
Author(s):  
Stéphane Niyoteka ◽  
Thomas Berger ◽  
Lars Ulrik Fokdal ◽  
Jørgen Breede Baltzer Petersen ◽  
Andras Zolnay ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Target Volume ◽  
Advanced Cervical Cancer ◽  
Internal Target ◽  
Internal Target Volume ◽  
Locally Advanced Cervical Cancer ◽  
Spot Scanning ◽  
Volume Strategy

scholarly journals Oncothermia in HIV-Positive and -Negative Locally Advanced Cervical Cancer Patients in South Africa

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Carrie A. Strauss ◽  
Jeffrey A. Kotzen ◽  
Ans Baeyens ◽  
Irma Maré
Keyword(s):  
South Africa ◽  
Cervical Cancer ◽  
Cancer Patients ◽  
Standard Treatment ◽  
Locally Advanced ◽  
External Beam Radiation ◽  
Hiv Positive ◽  
Advanced Cervical Cancer ◽  
Treatment Toxicity ◽  
Locally Advanced Cervical Cancer

Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity, quality of life, economic impact, and HIV status of participants. Radiobiology investigations will evaluate thermoradiosensitivity and the molecular markers for thermoradiosensitivity. Methodology. Phase III randomised clinical trial involving 236 HIV-negative and -positive stage IIb-III locally advanced cervical cancer patients. Treatment includes cisplatin, external beam radiation, and brachytherapy. The study group will receive oncothermia treatments. Participants will be monitored for two years after completion of treatment. Hypothesis. The addition of oncothermia to standard treatment protocols will result in improved clinical response without increasing treatment toxicity in HIV-positive patients or raising healthcare costs.

Detection of Human Papillomavirus Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association With Prognosis

1999 ◽  
Vol 17 (5) ◽  
pp. 1391-1391 ◽  
Author(s):  
Chih-Jen Tseng ◽  
Chia C. Pao ◽  
Jen-Daw Lin ◽  
Yung-Kuei Soong ◽  
Ji-Hong Hong ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Tumor Volume ◽  
Locally Advanced ◽  
Advanced Cervical Cancer ◽  
Hpv Dna ◽  
Locally Advanced Cervical Cancer ◽  
Gene Mrna ◽  
Specific Mrna

PURPOSE: To evaluate the feasibility of detecting human papillomavirus E6 (HPVE6) gene mRNA in the peripheral blood of patients with locally advanced cervical cancer, and the relationship of the circulating HPV viral–specific mRNA with clinicopathologic factors and prognosis of locally advanced cervical cancer.PATIENTS AND METHODS: The presence of types 16 and 18 HPVE6 gene mRNA was determined by reverse transcription followed by nested polymerase chain reaction. Thirty-five patients with locally advanced cervical cancer who were positive for HPV type 16 or 18 DNA were included in the study. All patients received external-beam radiation therapy followed by intracavitary brachytherapy.RESULTS: Eighteen (51.4%) of 35 HPV DNA–positive cervical cancer patients had HPV-specific mRNA in their peripheral blood cells, compared with none of 17 HPV DNA–negative cervical cancer patients and none of 12 control volunteers. The presence of HPVE6 gene mRNA in peripheral blood was associated with bulky tumor volume (> 4 cm) and pelvic lymph node metastasis (tumor volume, P = .03; lymph node status, P = .03). After a median follow-up of 22 months, patients who were positive for peripheral-blood HPVE6 gene mRNA had a significantly higher risk of recurrence than those who were negative (10 of 18 v three of 17, P = .02; mean recurrent time, 20.7 months v 12.6 months, P = .02). There was also a statistically significant association of peripheral-blood HPVE6 gene mRNA positivity with distant metastasis (eight of 18 v one of 17; P = .01).CONCLUSION: Results of this study seem to suggest that the presence of HPVE6 gene mRNA in peripheral blood may provide an early marker that identifies patients who are at risk for metastasis.

scholarly journals Reduction of dose to duodenum with a refined delineation method of Para-aortic region in patients with locally advanced cervical Cancer receiving prophylactic extended-field radiotherapy

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Bo Yang ◽  
Xiaoliang Liu ◽  
Ke Hu ◽  
Jie Qiu ◽  
Fuquan Zhang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Irradiation Dose ◽  
Locally Advanced ◽  
Volumetric Modulated Arc Therapy ◽  
Vena Cava ◽  
Target Volume ◽  
High Dose ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Extended Field

Abstract Background To compare irradiation dose to the second and third portions of duodenum (Duo2 and Duo3) with a new refined and old delineation method of para-aortic region for patients with locally advanced cervical cancer (LACC) receiving prophylactic extended-field radiotherapy (EFRT). Methods Twenty consecutive patients with LACC were treated with prophylactic EFRT from January 2016 to January 2017 at our institute. Two delineation methods of para-aortic region were designed for each patient, the old delineation method ensured a full coverage of aortic and inferior vena cava, while the right paracaval region above L3 was omitted from CTV in the new delineation method. Patients received a dose of 50.4Gy in 28 fractions for PCTV and a dose of 60.2Gy in 28 fractions for PGTV with volumetric-modulated arc therapy (VMRT). The dose delivered to Duo2 and Duo3 with these two delineation methods were compared. Results All treatment plans achieved excellent target volume coverage with 95% of PCTV receiving 50.4Gy and 95% of PGTV receiving 60.2Gy. There was no difference between delineation methods in low dose level (V5, V10, V15, V20, V25) for Duo2 and Duo3. The V30, V35, V40, V45, V50, Dmax, Dmean and D2cc for Duo2 with the new and old delineation methods were 55.76% vs 80.54% (P = 0.009), 34.72% vs 70.91% (P < 0.001), 18.69% vs 55.46% (P < 0.001), 8.20% vs 41.49% (P < 0.001), 1.86% vs 21.60% (P < 0.001), 49.58Gy vs 52.91Gy (P = 0.002), 30.38Gy vs 39.22Gy (P = 0.001) and 37.90Gy vs 48.64Gy (P < 0.001) respectively. For Duo3, the new delineation method achieved significant advantages in V30, V35, V40, V45, V50 and Dmean over the old one (96.82% vs 99.25%, P = 0.021; 89.65% vs 97.21%, P = 0.001; 79.50% vs 93.18%, P < 0.001; 65.63% vs 82.93%, P < 0.001; 43.39% vs 65.60%, P < 0.001; 46.09Gy vs 49.24Gy, P < 0.001), no deference was observed regarding D2cc and Dmax with these two delineation methods. Conclusion With the new delineation method of para-aortic area in prophylactic EFRT, significant reduction of irradiation dose to the second and third portions of duodenum in high dose area was obtained. This may further lower the incidence of duodenal toxicity when performing prophylactic EFRT for patients with LACC.

Sign in / Sign up

Export Citation Format

Share Document